Biosergen AB
Research Biosergen AB (8N10) on Bullrun: market cap EUR 4.97M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker8N10
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 4.97M
- Financial periodFY2025
- RevenueSEK 0
- Net income-SEK 40.82M
- Free cash flow-SEK 35.53M
Valuation Snapshot
latest market cap is EUR 4.97M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 40.82M | -SEK 35.53M | n/a | -17.31 | SEK 15.37M | n/a | SEK 8.12M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-17 | EUR 4.97M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Biosergen AB
Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biosergen AB's market cap?
Biosergen AB's market capitalization is EUR 4.97M.
What does Biosergen AB do?
Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.